SYNTHESIS AND SEROTONERGIC ACTIVITY OF N,N-DIMETHYL-2-[5-(1,2,4-TRIAZOL-1-YLMETHYL)-1H-INDOL-3-YL] ETHYLAMINE AND ANALOGS - POTENT AGONISTS FOR 5-HT1D RECEPTORS

被引:74
作者
STREET, LJ
BAKER, R
DAVEY, WB
GUIBLIN, AR
JELLEY, RA
REEVE, AJ
ROUTLEDGE, H
STERNFELD, F
WATT, AP
BEER, MS
MIDDLEMISS, DN
NOBLE, AJ
STANTON, JA
SCHOLEY, K
HARGREAVES, RJ
SOHAL, B
GRAHAM, MI
MATASSA, VG
机构
[1] MERCK SHARP & DOHME LTD,RES LABS,NEUROSCI RES CTR,DEPT BIOCHEM,HARLOW CM20 2QR,ESSEX,ENGLAND
[2] MERCK SHARP & DOHME LTD,RES LABS,NEUROSCI RES CTR,DEPT PHARMACOL,HARLOW CM20 2QR,ESSEX,ENGLAND
[3] MERCK SHARP & DOHME RES LABS,DEV LABS,DEPT PREDEV PHARMACOKINET,HODDESDON EN11 9BU,HERTS,ENGLAND
关键词
D O I
10.1021/jm00010a025
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The synthesis and the 5-HT receptor activity of a novel series of N,N-dimethyltryptamines substituted in the 5-position with an imidazole, triazole, or tetrazole ring are described. The objective of this work was to identify potent and selective 5-HT1D receptor agonists with high oral bioavailability and low central nervous system penetration. Compounds have been prepared in which the azole ring is attached through either nitrogen or carbon to the indole. Conjugated and methylene-bridged derivatives have been studied (n = 0 or 1). Substitution of the azole ring has been explored either alpha or beta to the point of attachment to indole. In a series of N-linked azoles (X = N), simple unsubstituted compounds have high affinity and selectivity for 5-HT1D receptors. It is proposed that for good affinity and selectivity a hydrogen bond acceptor interaction with the 5-HT1D receptor, through a beta-nitrogen in the azole ring, is required. In a series of C-linked triazoles and tetrazoles (X = C), optimal affinity and selectivity for the 5-HT1D receptor was observed when the azole ring is substituted at the 1-position with a methyl or ethyl group. This study has led to the discovery of the 1,2,4-triazole 10a (MK-462) as a potent and selective 5-HT1D receptor agonist which has high oral bioavailability and rapid oral absorption. The in vitro activity and the preliminary pharmacokinetics of compounds in this series are presented.
引用
收藏
页码:1799 / 1810
页数:12
相关论文
共 40 条
[1]   CLONING OF ANOTHER HUMAN SEROTONIN RECEPTOR (5-HT1F) - A 5TH 5-HT1 RECEPTOR SUBTYPE COUPLED TO THE INHIBITION OF ADENYLATE-CYCLASE [J].
ADHAM, N ;
KAO, HT ;
SCHECHTER, LE ;
BARD, J ;
OLSEN, M ;
URQUHART, D ;
DURKIN, M ;
HARTIG, PR ;
WEINSHANK, RL ;
BRANCHEK, TA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (02) :408-412
[2]  
[Anonymous], 1984, COMPR HETEROCYCL CHE, DOI [10.1016/B978-008096519-2.00080-1, DOI 10.1016/B978-008096519-2.00080-1]
[3]  
BAKER R, 1992, Patent No. 497512
[4]  
BARD JA, 1993, J BIOL CHEM, V268, P23422
[5]   AN INVESTIGATION OF THE 5-HT1D RECEPTOR-BINDING AFFINITY OF 5-HYDROXYTRYPTAMINE, 5-CARBOXYAMIDOTRYPTAMINE AND SUMATRIPTAN IN THE CENTRAL-NERVOUS-SYSTEM OF 7 SPECIES [J].
BEER, MS ;
STANTON, JA ;
BEVAN, Y ;
CHAUHAN, NS ;
MIDDLEMISS, DN .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1992, 213 (02) :193-197
[6]   5-HT(1)-LIKE RECEPTORS - 6 DOWN AND STILL COUNTING [J].
BEER, MS ;
MIDDLEMISS, DN ;
MCALLISTER, G .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1993, 14 (06) :228-231
[7]   L-694,247 - A POTENT 5-HT(1D) RECEPTOR AGONIST [J].
BEER, MS ;
STANTON, JA ;
BEVAN, Y ;
HEALD, A ;
REEVE, AJ ;
STREET, LJ ;
MATASSA, VG ;
HARGREAVES, RJ ;
MIDDLEMISS, DN .
BRITISH JOURNAL OF PHARMACOLOGY, 1993, 110 (03) :1196-1200
[8]   THE 5-HT4 RECEPTOR - A PLACE IN THE SUN [J].
BOCKAERT, J ;
FOZARD, JR ;
DUMUIS, A ;
CLARKE, DE .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1992, 13 (04) :141-145
[9]   RECEPTOR DIVERSITY - MORE SEROTONIN RECEPTORS [J].
BRANCHEK, T .
CURRENT BIOLOGY, 1993, 3 (05) :315-317
[10]   THE ANTIMIGRAINE DRUG, SUMATRIPTAN (GR43175), SELECTIVELY BLOCKS NEUROGENIC PLASMA EXTRAVASATION FROM BLOOD-VESSELS IN DURA MATER [J].
BUZZI, MG ;
MOSKOWITZ, MA .
BRITISH JOURNAL OF PHARMACOLOGY, 1990, 99 (01) :202-206